About Vectura

Inhalation is our focus. With more than 20 years’ experience, we can help you succeed in bringing inhaled medicines to market.

Track Record

Our partners have succeeded in bringing DPI, pMDI and nebuliser medicines to market with the help of our specialist capabilities.

Our combination of formulation science, device technology and inhaled development expertise has contributed to the success of 13 inhaled medicines, launched by our partners and licensees.

Since launch, they have generated $11 billion in sales and in 2020 these products were used by 10 million patients worldwide.

More information


years' experience in inhaled product development


inhaled on-market medicines, launched by our partners and licensees


total sales of products using our formulation and device technology since launch


patients using products utilising Vectura’s intellectual property in 2020